HC Wainwright Reiterates Neutral Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $4.10 price target on the stock. HC Wainwright’s target price points to a potential upside of 3.02% from the company’s previous close.

Several other research firms have also commented on CKPT. Lake Street Capital reiterated a “hold” rating and issued a $4.10 price objective (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday. D. Boral Capital reaffirmed a “buy” rating and issued a $4.80 target price (down from $9.00) on shares of Checkpoint Therapeutics in a report on Monday.

Checkpoint Therapeutics Price Performance

Shares of CKPT stock opened at $3.98 on Tuesday. The firm has a 50-day moving average of $3.10 and a 200-day moving average of $3.08. Checkpoint Therapeutics has a one year low of $1.38 and a one year high of $4.50. The company has a market cap of $194.36 million, a P/E ratio of -2.16 and a beta of 1.41.

Insider Transactions at Checkpoint Therapeutics

In related news, CEO James F. Oliviero III sold 10,331 shares of Checkpoint Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the sale, the chief executive officer now owns 3,775,019 shares of the company’s stock, valued at approximately $11,891,309.85. The trade was a 0.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO William Garrett Gray sold 74,110 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the transaction, the chief financial officer now owns 1,458,644 shares in the company, valued at approximately $5,353,223.48. The trade was a 4.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 582,336 shares of company stock worth $2,156,801 in the last ninety days. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CKPT. Virtu Financial LLC bought a new stake in Checkpoint Therapeutics in the 3rd quarter valued at about $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Checkpoint Therapeutics in the fourth quarter valued at approximately $32,000. PUREfi Wealth LLC purchased a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at approximately $32,000. Stifel Financial Corp purchased a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at approximately $32,000. Finally, Ameriflex Group Inc. bought a new position in Checkpoint Therapeutics in the 4th quarter worth approximately $32,000. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.